The Control of Neuromuscular Transmission in Health and Disease

The Neuroscientist

Volumn 12, Issue 2, 2006, Pages 134-142

  Rich, Mark M ^a  

^a WRIGHT STATE UNIVERSITY   (United States)

Author keywords

Lambert Eaton myasthenic syndrome; Motor neuron disease; Myasthenia gravis; Neuromuscular junction; Neuronal plasticity; Synaptic; transmission

Indexed keywords

ACETYLCHOLINE; CHOLINERGIC RECEPTOR;

ANIMAL; ELECTROPHYSIOLOGY; ELECTROSTIMULATION; HUMAN; INNERVATION; INSTRUMENTATION; METABOLISM; METHODOLOGY; MOTONEURON; NEUROMUSCULAR JUNCTION DISORDER; NEUROMUSCULAR SYNAPSE; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SKELETAL MUSCLE; SYNAPTIC TRANSMISSION;

ACETYLCHOLINE; ANIMALS; ELECTRIC STIMULATION; ELECTROPHYSIOLOGY; HUMANS; MOTOR NEURONS; MUSCLE, SKELETAL; NEUROMUSCULAR JUNCTION; NEUROMUSCULAR JUNCTION DISEASES; RECEPTORS, CHOLINERGIC; SYNAPTIC TRANSMISSION;

EID: 33646678454     PISSN: 10738584     EISSN: None     Source Type: Journal    
DOI: 10.1177/1073858405281898     Document Type: Review

References (51)

1. Balice-Gordon RJ, Smith DB, Goldman J. Cork LC, Shirley A, Cope TC, Pinter MJ. 2000. Functional motor unit failure precedes neuromuscular degeneration in canine motor neuron disease. Ann Neurol 47: 596–605.
2. Barstad JA, Lilleheil G. 1968. Transversaly cut diaphragm preparation from rat. An adjuvant tool in the study of the physiology and pharmacology of the myoneural junction. Arch Int Pharmacodyn Ther 175: 373–390.
3. Boyd IA, Martin AR. 1956. The end-plate potential in mammalian muscle. J Physiol 132: 74–91.
4. Cull-Candy SG, Miledi R. Trautmann A. 1978. Acetylcholine-induced channels and transmitter release at human endplates. Nature 271: 74–75.
5. Drachman DB. 1994. Myasthenia gravis. N Engl J Med 330: 1797– 810.
6. Elmqvist D. Hofmann WW, Kugelberg J, Quastel DM. 1964. An electrophysiological investigation of neuromuscular transmission in myasthenia gravis. J Physiol 174: 417–434.
7. Elmqvist D. Lambert EH. 1968. Detailed analysis of neuromuscular transmission in a patient with the myasthenic syndrome sometimes associated with bronchogenic carcinoma. Mayo Clin Proc 43: 689–713.
8. Engisch KL, Rich MM, Cook N. Nowycky MC. 1999. Lambert-Eaton antibodies inhibit Ca2+ currents but paradoxically increase exocytosis during stimulus trains in bovine adrenal chromaffin cells. J Neurosci 19: 3384–3395.
9. Fischer LR, Culver DG, Tennant P, Davis AA, Wang M, Castellano-Sanchez A, and others. 2004. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol 185: 232–240.
10. Frey D. Schneider C, Xu L, Borg J, Spooren W, Caroni P. 2000. Early and selective loss of neuromuscular synapse subtypes with low sprouting competence in motoneuron diseases. J Neurosci 20: 2534–2542.
11. Giovannini F. Sher E, Webster R, Boot J, Lang B. 2002. Calcium channel subtypes contributing to acetylcholine release from normal, 4-aminopyridine-treated and myasthenic syndrome auto-antibodiesaffected neuromuscular junctions. Br J Pharmacol 136: 1135–1145.
12. Glavinovic MI. 1979a. Presynaptic action of curare. J Physiol 290: 499– 506.
13. Glavinovic MI. 1979b. Voltage clamping of unparalysed cut rat diaphragm for study of transmitter release. J Physiol 290: 467–480.
14. Gooch JL. 1995. AAEM case report #29: prolonged paralysis after neuromuscular blockade. Muscle Nerve 18: 937–942.
15. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, and others. 1994. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264: 1772–1775.
16. Hamilton BR, Smith DO. 1991. Autoreceptor-mediated purinergic and cholinergic inhibition of motor nerve terminal calcium currents in the rat. J Physiol 432: 327–341.
17. Hille B. 2001. Ion channels of excitable membranes. 3rd ed. Sunderland, MA: Sinauer Associates.
18. Kao I. Drachman DB. 1977. Myasthenic immunoglobulin accelerates acetylcholine receptor degradation. Science 196: 527–529.
19. Katz E. Ferro PA, Weisz G, Uchitel OD. 1996. Calcium channels involved in synaptic transmission at the mature and regenerating mouse neuromuscular junction. J Physiol 497(Pt 3):687–697.
20. Kennel PF, Finiels F. Revah F. Mallet J. 1996. Neuromuscular function impairment is not caused by motor neurone loss in FALS mice: an electromyographic study. Neuroreport 7: 1427–1431.
21. Kimura J. 2001. Electrodiagnosis in diseases of nerve and muscle: principles and practice. 3rd ed. New York: Oxford University Press.
22. Lomo T. Rosenthal J. 1972. Control of ACh sensitivity by muscle activity in the rat. J Physiol 221: 493–513.
23. Lundberg A. Quilisch H. 1953. On the effect of calcium on presynaptic potentiation and depression at the neuro-muscular junction. Acta Physiol Scand Suppl 111: 121–129.
24. Magleby KL, Pallotta BS. 1981. A study of desensitization of acetylcholine receptors using nerve-released transmitter in the frog. J Physiol 316: 225–250.
25. Malinowski MN, Cannady SB, Schmit KV, Barr PM, Schrock JW, Wilson DF. 1997. Adenosine depresses transmitter release but is not the basis for ‘tetanic fade’ at the neuromuscular junction of the rat. Neurosci Lett 230: 81–84.
26. Otis T. Zhang S, Trussell LO. 1996. Direct measurement of AMPA receptor desensitization induced by glutamatergic synaptic transmission. J Neurosci 16: 7496–7504.
27. Pennefather P. Quastel DM. 1982. Fast desensitization of the nicotinic receptor at the mouse neuromuscular junction. Br J Pharmacol 77: 395–404.
28. Person RS, Kudina LP. 1972. Discharge frequency and discharge pattern of human motor units during voluntary contraction of muscle. Electroencephalogr Clin Neurophysiol 32: 471–483.
29. Pinter MJ, Cope TC, Cork LC, Green SL, Rich MM. 2001. Canine motor neuron disease: a view from the motor unit. In: Cope TC, editor. Motor neurobiology of the spinal cord. New York: CRC Press. p 231–250.
30. Pinter MJ, Waldeck RF, Cope TC, Cork LC. 1997. Effects of 4-aminopyridine on muscle and motor unit force in canine motor neuron disease. J Neurosci 17: 4500–4507.
31. Plomp JJ, Van Kempen GT, De Baets MB, Graus YM, Kuks JB, Molenaar PC. 1995. Acetylcholine release in myasthenia gravis: regulation at single end-plate level. Ann Neurol 37: 627–636.
32. Plomp JJ, van Kempen GT, Molenaar PC. 1992. Adaptation of quantal content to decreased postsynaptic sensitivity at single endplates in alpha-bungarotoxin-treated rats. J Physiol 458: 487–499.
33. Preston DC, Shapiro BE. 1998. Electromyography and neuromuscular disorders: clinical-electrophysiologic correlations. Boston: Butterworth-Heinemann.
34. Redman RS, Silinsky EM. 1993. A selective adenosine antagonist (8-cyclopentyl-1,3-dipropylxanthine) eliminates both neuromuscular depression and the action of exogenous adenosine by an effect on A1 receptors. Mol Pharmacol 44: 835–840.
35. Rich MM, Bird SJ, Raps EC, McCluskey LF, Teener JW. 1997. Direct muscle stimulation in acute quadriplegic myopathy. Muscle Nerve 20: 665–673.
36. Rich MM, Colman H. Lichtman JW. 1994. In vivo imaging shows loss of synaptic sites from neuromuscular junctions in a model of myasthenia gravis. Neurology 44: 2138–2145.
37. Rich MM, Teener JW, Raps EC, Schotland DL, Bird SJ. 1996. Muscle is electrically inexcitable in acute quadriplegic myopathy [see Comments]. Neurology 46: 731–736.
38. Rich MM, Wang X. Cope TC, Pinter MJ. 2002. Reduced neuromuscular quantal content with normal synaptic release time course and depression in canine motor neuron disease. J Neurophysiol 88: 3305–3314.
39. Robitaille R. Charlton MP. 1992. Presynaptic calcium signals and transmitter release are modulated by calcium-activated potassium channels. J Neurosci 12: 297–305.
40. Ruff RL, Lennon VA. 1998. End-plate voltage-gated sodium channels are lost in clinical and experimental myasthenia gravis. Ann Neurol 43: 370–379.
41. Sanders DB. 2003. Lambert-Eaton myasthenic syndrome: diagnosis and treatment. Ann N Y Acad Sci 998: 500–508.
42. Santafe MM, Salon I. Garcia N, Lanuza MA, Uchitel OD, Tomas J. 2003. Modulation of ACh release by presynaptic muscarinic autoreceptors in the neuromuscular junction of the newborn and adult rat. Eur J Neurosci 17: 119–127.
43. Snider WD, Harris GL. 1979. A physiological correlate of disuse-induced sprouting at the neuromuscular junction. Nature 281: 69–71.
44. Stalberg E. Schwartz MS, Trontelj JV. 1975. Single fibre electromyography in various processes affecting the anterior horn cell. J Neurol Sci 24: 403–415.
45. Takamori M. Sakato S, Okumura S. 1984. Presynaptic function modified by acetylcholine-receptor interaction in experimental autoimmune myasthenia gravis. J Neurol Sci 66: 245–253.
46. Tsujimoto T. Umemiya M, Kuno M. 1990. Terminal sprouting is not responsible for enhanced transmitter release at disused neuromuscular junctions of the rat. J Neurosci 10: 2059–2065.
47. Vincent A, McConville J, Farrugia ME, Bowen J, Plested P, Tang T, and others. 2003. Antibodies in myasthenia gravis and related disorders. Ann N Y Acad Sci 998: 324–335.
48. Wang X. Engisch KL, Li Y, Pinter MJ, Cope TC, Rich MM. 2004. Decreased synaptic activity shifts the calcium dependence of release at the mammalian neuromuscular junction in vivo. J Neurosci 24: 10687–10692.
49. Wood SJ, Slater CR. 2001. Safety factor at the neuromuscular junction. Prog Neurobiol 64: 393–429.
50. Xu J. Wu LG. 2005. The decrease in the presynaptic calcium current is a major cause of short-term depression at a calyx-type synapse. Neuron 46: 633–645.
51. Zucker RS, Regehr WG. 2002. Short-term synaptic plasticity. Annu Rev Physiol 64: 355–405.